finanzwire.de

Search

IBA (EBR:IBAB) IBA SA : DATA CONCERNING TRANSPARENCY

Transparency directive : regulatory news

21/11/2017 18:00

12/01/2018 18:00
05/01/2018 07:20
05/01/2018 07:15
21/11/2017 18:00
16/11/2017 07:00
10/10/2017 07:00
23/09/2017 16:00
24/08/2017 07:00
23/08/2017 18:00
14/07/2017 17:50

IBA - DATA CONCERNING TRANSPARENCY
Heading II of the law of May 2, 2007 and the Royal Decree of February 14, 2008

Louvain-la-Neuve, Belgium, November 21, 2017 - IBA (Ion Beam Applications SA), the world`s leading provider of proton therapy solutions for the treatment of cancer, communicates today the basic and additional data as per Article 15 §1 al.1 of the Transparency Law, following its capital increase (further to exercises of stock options) dated November 17, 2017.

Communication of the basic data as per Article 15 §1 al.1 of the Law

  • Total capital: EUR 42 053 237,84 
  • Total number of securities conferring the voting right: 29 962 246
  • Total number of voting rights (= the denominator): 29 962 246
  • Total number of securities conferring the voting right, by category: N/A
  • Total number of voting rights, by category: N/A

Communication of the additional data as per Article 15 §1 al.2 of the Law

  • Total number of convertible bonds conferring the voting right: 0
  • Total number of rights, materialized or not by certificates, giving the right to subscribe to newly issued securities conferring the voting right (e.g. warrants): 400 153
  • Total number of voting rights which would result from the exercise ofthese conversion or subscription rights: 400 153
  • Total number of shares without voting right: 0

Statutory thresholds as per Article 18 of the Law

The applicable thresholds as follows: three percent, five percent, ten percent, fifteen percent and so on by brackets of five percent

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA`s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

For further information, please contact:

IBA
Stephanie Bauwin
Legal Counsel
+32 10 203 924
Stephanie.bauwin@iba-group.com